HEMLIBRA (emicizumab), haemostatic
Reason for request
High clinical benefit for the prophylaxis of bleeding episodes in congenital haemophilia A with high-titer anti-factor VIII inhibitor and significant clinical added value overFEIBA and NOVOSEVEN
Insufficient clinical benefit to justify its reimbursement for the prophylaxis of bleeding episodes in congenital haemophilia A without high-titer anti-factor VIII inhibitor
-
HEMLIBRA has been granted a marketing authorisation for the prevention of bleeding episodes in patients with haemophilia A who have developed an anti-factor VIII inhibitor.
-
This monoclonal antibody mimics FVIII activity. It is administered via a once-weekly subcutaneous (SC) injection.
-
The clinical data, even though the level of evidence is sub-optimal, suggest that the efficacy of HEMLIBRA is greater than prophylaxis with bypassing agents (FEIBA and NOVOSEVEN). It is expected to offer a major quality of life benefit for patients by comparison to these treatments.
-
The SPC must be consulted for the interpretation of coagulation tests (interference with HEMLIBRA) and in the event of concomitant administration of a bypassing agent (interaction with FEIBA), considering the risks of thrombotic microangiopathy and thromboembolic events.
Clinical Benefit
Substantial |
- |
Insufficient |
Clinical Added Value
important |
- |
Not applicable |
-